A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study week 12 in patients with neovascular (wet) age-related macular degeneration

Trial Profile

A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study week 12 in patients with neovascular (wet) age-related macular degeneration

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms TIDE AMD
  • Sponsors Novartis
  • Most Recent Events

    • 25 Nov 2017 Status changed from recruiting to discontinued.
    • 29 Sep 2017 Planned End Date changed from 3 Sep 2017 to 15 Dec 2017.
    • 29 Sep 2017 Planned primary completion date changed from 3 Sep 2017 to 15 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top